Recent reports indicated that serum LOX-1 could also be a potential biomarker for monitoring the severity of inflammation and oxidative stress, or for the prediction of prognoses in patients with arteriosclerosis, obstructive sleep apnea (OSA), or neonatal hypoxic-ischemic encephalopathy [26,27,28]. This evidence concerns the gene OLR1 and arteriosclerosis.